Join
Live feed
·
PRReleasevia Quantisnow
Global Blood Therapeutics Inc. logo

GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition

ByQuantisnow·Wall Street's wire, on your screen.
GBT· Global Blood Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GBT (Global Blood Therapeutics Inc.) and more on Quantisnow.